Open AccessAn evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II
Author(s) -
Bernard Floccard,
Hautin,
Laurence Bouillet,
Coppere,
Allaouchiche
Publication year - 2012
Publication title -
core evidence
Language(s) - English
Resource type - Journals
eISSN - 1555-175X
pISSN - 1555-1741
DOI - 10.2147/ce.s24743
Subject(s) - icatibant , hereditary angioedema , medicine , angioedema , dermatology , intensive care medicine , bradykinin , anesthesia , receptor
Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom